School of Medicine
Showing 1-6 of 6 Results
Blake K. Scanlon, Ph.D.
Adjunct Lecturer, Psych/Public Mental Health & Population Sciences
BioThe overarching aim of Dr. Scanlon’s research is to develop and evaluate low-cost, pragmatic and clinically translatable methods for improving management of neurodegenerative disease and dementia. To that end, the Caregiver Technology Division of the Scanlon Lab aims to enhance patient- and family-centered care through novel, broadly customizable, and highly scalable caregiver interventions. In parallel, the Neurodegenerative Division of the Scanlon Lab focuses on the development and application of cognitive, neuropsychiatric, and biological markers for the initiation and progression of neurodegeneration.
Dr. Scanlon received his bachelor’s degree in Neuroscience and doctorate in Clinical Health Psychology from the University of Miami. After concluding his clinical internship in Geropsychology/Neuropsychology at the VA Palo Alto Health Care System (VAPAHCS), he completed fellowships in Aging and Dementia at Stanford University School of Medicine and VAPAHCS. Dr. Scanlon is currently a VA Career Development Awardee in the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) and Stanford/VA Aging Clinical Research Center where his work focuses on developing and evaluating low-cost, pragmatic and clinically translatable methods for improving management of neurodegenerative disease and dementia. He also serves as Co-Director of the Stanford/VA California Alzheimer's Disease Center, Chair of the VAPAHCS Dementia Committee, and Co-Chair of the Department of Veterans Affairs VISN 21 Dementia Committee.
Clinical Assistant Professor (Affiliated) [Vapahcs], Psych/Public Mental Health & Population Sciences
Staff, Psych/Public Mental Health & Population Sciences
Current Research and Scholarly InterestsFrom a research perspective, my long-term career plan is to refine the understanding of normal and dysfunctional sleep, much like the Epilepsy Phenome/Genome Project (EPGP) and Epi4K are doing for the enigmatic epilepsies. Insufficient sleep has been deemed a public health problem with poorly understood behavioral and physiologic sleep disorders lying at the core of the issue. I am currently using well-defined distinct and objective phenotypes (e.g. periodic limb movements, hypocretin-deficient narcolepsy) to acquire the analytic skills necessary to expand my knowledge of both signal processing and genetics, with the former enhancing my ability to identify and/or refine sleep phenotypes, and the latter facilitating the pathophysiological understanding of these phenotypes. As a consequence of a better link between symptoms/phenotypes, physiology, and genetic risks, more personally targeted and effective therapeutics can be developed to address the enriched spectrum of sleep disorders.
Ana Lilia Soto
Youth Development Manager, Psych/Public Mental Health & Population Sciences
Current Role at StanfordYouth Development Manager